Phase I study of pemetrexed with sorafenib in advanced solid tumors.
about
The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxideHDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.
P2860
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
@en
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
@nl
type
label
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
@en
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
@nl
prefLabel
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
@en
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
@nl
P2093
P2860
P356
P1433
P1476
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
@en
P2093
Andrew Poklepovic
Charles E Geyer
Danielle A Shafer
Ellen Shrader
H Davis Massey
John D Roberts
Katie Strickler
Laurence Booth
Maciej Kmieciak
Maria Quigley
P2860
P304
42625-42638
P356
10.18632/ONCOTARGET.9434
P407
P50
P577
2016-05-18T00:00:00Z